ARTL · Artelo Biosciences, Inc.
$6.52
+0.37 (+5.93%)
At close · Sep 2
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$3.33M
Shares
510,563
ARTL metrics
30 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$6.52
Market cap
$3.33M
Price action
19 metricsPrice change (1W)
—
Price change (30D)
-3.2%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
510,563
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 153.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-390.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.07M
Net income (TTM)
−$12.67M
Trailing 12 months
Diluted EPS (TTM)
$-119.07
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,319.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-253.6%
Return on assets
-196.2%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.0
Interest coverage
-48.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.20M
Total assets
$6.46M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$12.63M
Capital expenditures (TTM)
—
R&D (TTM)
$3.82M
SG&A (TTM)
—
Stock compensation (TTM)
$1.77M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
10
13F filer change QoQ
-1
Institutional ownership
2.5%
Short interest
3 metricsShort interest
1.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
37 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1621221
CUSIP
04301G706
13F (30d)
11 filings
11 filers
Visit website
Investor relations